97 related articles for article (PubMed ID: 15136052)
1. Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis.
Jovin IS; Müller-Berghaus G
Atherosclerosis; 2004 Jun; 174(2):225-33. PubMed ID: 15136052
[TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease.
Caputo M; Mantini G; Floriani I; Ciceri M; Noseda A; Bonomo L
Eur Heart J; 1996 Sep; 17(9):1329-36. PubMed ID: 8880017
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a), fibrin binding, and plasminogen activation.
Loscalzo J; Weinfeld M; Fless GM; Scanu AM
Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
5. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
6. The fibrinolytic system in neoplasia.
Bell WR
Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
8. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Shen GX
Int J Mol Med; 1998 Feb; 1(2):399-408. PubMed ID: 9852242
[TBL] [Abstract][Full Text] [Related]
9. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
10. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
11. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
12. Secretion of fibrinolytic enzymes facilitates human mesenchymal stem cell invasion into fibrin clots.
Neuss S; Schneider RK; Tietze L; Knüchel R; Jahnen-Dechent W
Cells Tissues Organs; 2010; 191(1):36-46. PubMed ID: 19390164
[TBL] [Abstract][Full Text] [Related]
13. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
Idell S
Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
[TBL] [Abstract][Full Text] [Related]
14. [Lipoprotein-mediated functional changes in the fibrinolytic system in the genesis of atherosclerosis].
García Frade LJ; García Avello A
Sangre (Barc); 1991 Feb; 36(1):25-8. PubMed ID: 1649496
[No Abstract] [Full Text] [Related]
15. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
16. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner.
Edelberg JM; Pizzo SV
Blood Coagul Fibrinolysis; 1991 Dec; 2(6):759-64. PubMed ID: 1839224
[TBL] [Abstract][Full Text] [Related]
18. Effects of cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients.
Ahaneku JE; Sakata K; Uranol T; Takada Y; Takada A
Drugs Exp Clin Res; 2000; 26(4):119-23. PubMed ID: 11109511
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
